U.S. Markets open in 27 mins.

Elite Pharmaceuticals, Inc. (ELTP)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1770.00 (0.00%)
At close: 3:59PM EDT
People also watch
AMBSONCSIGXTMSTXRNN
Interactive chart
Previous Close0.177
Open0.000
Bid0.000 x
Ask0.000 x
Day's Range0.000 - 0.000
52 Week Range
Volume0
Avg. Volume990,304
Market Cap137.27M
Beta0.19
PE Ratio (TTM)5.71
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Elite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: Q3, 2017 By the Numbers : March 15, 2017
    Capital Cube2 months ago

    Elite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: Q3, 2017 By the Numbers : March 15, 2017

    Categories: Yahoo Finance Get free summary analysis Elite Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Elite Pharmaceuticals, Inc. – Mylan N.V., Cambrex Corporation, Aceto Corporation, Nektar Therapeutics, Pfizer Inc., Albany Molecular Research, Inc. and Akorn, Inc. (MYL-US, CBM-US, ACET-US, NKTR-US, PFE-US, AMRI-US and ... Read more (Read more...)

  • TheStreet.com9 months ago

    Trending Tickers: CZR, APO, MCUR, KS, ELTP

    Caesars shares sink after a judge ruled that it would not be shielded from $11 billion in bondholder lawsuits.

  • Capital Cube10 months ago

    Elite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016

    Click here to see latest analysisElite Pharmaceuticals, Inc. reports financial results for the year ended March 31, 2016.HighlightsGross margins widened from 27.61% to 58.80% compared to the same period last year, operating (EBITDA) margins now -61.22% from -316.83%.Change in operating cash flow of 81.69% compared to same period last year is about the same as […] (Read more...) The post Elite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 appeared first on CapitalCube.